Janssen unveils long-term data for HIV drug Symtuza
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV.
Read More
Tag: cobicistat
US approves Janssen’s HIV pill Symtuza
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
Read More
Janssen’s HIV combo pill hits safety, efficacy targets
Janssen Pharmaceutica’s experimental combination therapy for HIV containing four medicines in a single pill has hit safety and efficacy targets in a late stage trial, results of which have been published in The Lancet HIV.
Read More
Eleven medicines leap closer to EU approval
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
Janssen files HIV combination therapy in Europe
Janssen-Cilag has submitted a marketing application to the European Medicines Agency for a new once-daily darunavir-based single tablet regimen (STR) to treat HIV.
Read More
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
